NEW YORK - Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the Covid-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.
They are also testing a fourth dose of the current vaccine against a fourth dose of the Omicron-based vaccine in people who received a third dose of the Pfizer/BioNTech vaccine three to six months earlier. "While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalisation with Omicron, we recognise the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," Pfizer's head of vaccine research and development, Kathrin Jansen, said in a statement.
Pfizer has said that two doses of the original vaccine may not be sufficient to protect against infection from Omicron, and that protection against hospitalisations and deaths may be waning.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer and BioNTech launch trial of Omicron-targeted COVID-19 vaccineNEW YORK: Pfizer and BioNTech said on Tuesday (Jan 25) they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. The companies plan to test the
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Pfizer-BioNTech begin Omicron vaccine trialPfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday. When will people ever learn that they will never be able to catch up with the latest virus strain. Its the same mistake they are making again as with Alpha strain. In the end docile civilians are the guinea pigs for these live RCT experiments which only profit Big Pharma pockets.
Source: YahooSG - 🏆 3. / 71 Read more »
Pfizer and BioNTech launch trial of Omicron-targeted Covid-19 vaccineOmicron targeted vaccine by Pfizer ScottMorrisonMP GregHuntMP BradHazzard ChrisMinnsMP
Source: STForeignDesk - 🏆 4. / 71 Read more »
Pfizer and BioNTech launch trial of Omicron-targeted Covid vaccineNEW YORK — Pfizer and BioNTech said on Tuesday (Jan 25) they started a clinical trial to test a new version of their vaccine specifically designed to target the Covid-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. Crypto trading is best investment when trading with and expert in trading If you wanna earn from trading send a text to Mrs stephinieweller and start trading earn 100% profits with hood signals and mentorship.
Source: TODAYonline - 🏆 1. / 99 Read more »
Sinovac regimen gets strong boost from Pfizer, AstraZeneca or J&J Covid-19 shots
Source: STForeignDesk - 🏆 4. / 71 Read more »
Advocacy group urges Pfizer to sell more COVID-19 pills to developing countriesNEW YORK: An influential consumer advocacy group is pressing Pfizer to supply more of its new COVID-19 pill Paxlovid to developing countries this year, concerned that access to the treatment will mirror inequalities in vaccines. Public Citizen sent a letter to Pfizer chief executive Albert Bourla on M
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »